As the patents for "blockbusters"—drugs with annual sales exceeding $1 billion (approximately 1.4 trillion won)—approach ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...

Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.

Most patients with atopic dermatitis expressed an interest in understanding how environmental-climate factors affect their AD.

Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.

Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market ...

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...